Rituximab, initially approved in 1997 by the US FDA for use in relapsed/refractory indolent non-Hodgkin lymphoma (NHL) and subsequently in other indications, was the first monoclonal antibody (mAb) utilized in oncology and remains widely used over two decades later [1].
When was rituximab made?
It plays a key role in increasing survival for patients with NHL. Prior to the introduction of rituximab in 1997, the number of new cases of NHL increased each year.
How was rituximab discovered?
Research and Development History of Rituximab
The discovery was accomplished by Lee Nadler from the Dana Farber Cancer Institute in 1980. Nadler also created murine antibodies against CD20 using the Köhler-Milstein technique4 and administered them to lymphoma patients.
When did FDA approve rituximab?
On December 2, 2021, the FDA approved rituximab (brand name Rituxan) in combination with chemotherapy for pediatric patients 6 months to 18 years with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.
What is the success rate of rituximab?
Rituximab with bendamustine (Treanda, Cephalon) was studied in a phase 2 trial in patients with relapsed disease. This combination was found to be very effective, with an ORR of 92%.
17 related questions foundDoes rituximab lower immune system?
Rituximab suppresses the immune system. Therefore, serious fungal, bacterial, and new or reactivated viral infections (for example, hepatitis B or C, shingles) can occur during or after treatment with rituximab. Generally, rituximab is avoided in the presence of active, significant infections.
How do you know if rituximab is working?
Rituximab works by lowering the number of these B-cells, to reduce inflammation, pain, swelling and joint damage. If rituximab works for you, you'll probably notice an improvement in your symptoms 8-16 weeks after you start treatment.
How long has rituximab been on the market?
This chimeric technology was the basis for rituximab production, and in 1997 the FDA approved rituximab, brand name Rituxan, for use to treat follicular lymphoma (FL) (7). Rituximab was created by Ronald Levy for the express purpose of targeting malignant B cells.
Who owns Rituxan?
The pharmacokinetics of all three products was similar. No launch date for Ruxience has been announced, but Pfizer settled with Roche, Genentech's parent company, earlier this year over a key patent for the brand-name rituximab. There is already a biosimilar on the market for rituximab, Celltrion and Teva's Truxima.
Who makes rituximab?
Rituxan (Rituximab) is a monoclonal antibody indicated for treating advanced follicular lymphoma. The drug was developed by Biogen Idec and is co-promoted by Genentech, a subsidiary of Roche Group. Rituxan was approved by the US Food and Drug Administration (FDA) in 1997 for treating non-Hodgkin's lymphoma.
Is rituximab an immunotherapy?
Rituximab was approved by the US Food and Drug Administration for use in DLBCL nearly 20 years ago. It was the first immunotherapy approved for specific use in cancer, and it quickly demonstrated a dramatic improvement in outcomes in patients with DLBCL when combined with chemotherapeutic agents.
What is the difference between RITUXAN and rituximab?
Rituxan is the trade name for rituximab. In some cases, health care professionals may use the trade name rituxan when referring to the generic drug name rituximab. Drug type: Rituximab is a monoclonal antibody. (For more detail, see "How this drug works" section below).
Is rituximab a chemo drug?
RITUXAN is not chemotherapy. RITUXAN is a type of antibody therapy that can be used alone or with chemotherapy. They work in different ways to find and attack the cells where cancer starts. RITUXAN targets and attaches to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells.
What is rituximab made from?
Rituximab is a highly purified 1328-amino acid chimeric mouse/human antibody that is produced in mammalian cell culture using Chinese Hamster Ovary (CHO) cells. This IgG1 kappa antibody contains murine light and heavy chain variable regions, and human gamma 1 heavy chain and kappa light chain constant regions.
Is rituximab a steroid?
Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Development of steroid dependency in patients with nephrotic syndrome may require a long-term multi-drug therapy at risk of drug toxicity and renal failure.
How long does rituximab stay in the body?
Also, Rituxan may stay in your system 6 to 12 months after your last dose. Because of this, it can be used as a maintenance (long-term) treatment in certain cases.
What diseases is Rituxan used for?
Rituximab injection is used alone or together with other medicines to treat a type of cancer called non-Hodgkin's lymphoma (NHL). It is also used in combination with other cancer medicines to treat mature B-cell non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-AL).
How many times can rituximab be given?
Administer RITUXAN as a single-agent every 8 weeks for 12 doses. Following completion of 6-8 cycles of CVP chemotherapy, administer once weekly for 4 doses at 6-month intervals to a maximum of 16 doses. Administer on Day 1 of each cycle of chemotherapy for up to 8 infusions.
Is Rituxan chemotherapy or immunotherapy?
Rituxan (rituximab) is a monoclonal antibody medication that treats different types of blood cancer. Rituxan is also an immunotherapy medication, meaning it helps make the immune system better at fighting cancer. Different Rituxan formulations and biosimilars are available.
Is Rituxan humanized?
Rituximab is a chimeric mAb that is partially humanized, that has a human Fc portion but retains the murine variable region which recognizes CD20. Both ofatumumab and obinutuzumab are fully humanized mAbs, which reduces unintended immune responses against the therapies.
How will I feel after rituximab infusion?
After a Rituxan (rituximab) infusion you may experience certain side effects or adverse reactions that make you feel unwell. Rituxan affects different people in different ways, but the more common side effects include: Fever (high temperature), muscle aches, headaches and chills, which are signs of infection.
Will I lose my hair with rituximab?
Hair loss. You could lose all your hair. This includes your eyelashes, eyebrows, underarm, leg and sometimes pubic hair. Your hair will usually grow back once treatment has finished but it is likely to be softer.
How long is rituximab Covid vaccine?
Fifteen of the 126 patients had been fully vaccinated against COVID-19 prior to starting rituximab treatment, most just a few weeks before. Ten of these patients generated a blocking antibody response to the virus. In six of them, that response persisted at least four months after they started rituximab treatment.
Is there an alternative to rituximab?
Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab.
